Showing 1,841 - 1,860 results of 101,955 for search '(( 6 point decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.46s Refine Results
  1. 1841

    S5 Table - by Amábilli de Souza Rosar (20536911)

    Published 2025
    “…<i>infantum</i> were assessed at three time points: on the day before initiating miltefosine treatment (T0), immediately after treatment completion (T1), and 6 months after treatment completion (T2). …”
  2. 1842
  3. 1843
  4. 1844
  5. 1845

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  6. 1846

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  7. 1847
  8. 1848
  9. 1849
  10. 1850
  11. 1851
  12. 1852
  13. 1853
  14. 1854
  15. 1855
  16. 1856
  17. 1857
  18. 1858
  19. 1859

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
  20. 1860